Background: Patients undergoing femoral fracture surgery frequently require blood transfusion. Tranexamic acid (TXA) has been widely used to decrease transfusion rate in joint replacement surgery. Therefore, we conducted a systematic review to evaluate the efficacy and safety of TXA usage in femoral fracture surgery. Materials and methods: Studies involving TXA usage in femoral fracture surgery were searched through four electronic databases. The end points included total blood loss, postoperative hemoglobin decline, transfusion rate, thromboembolic events, 90-day mortality, and operative time. The present study was performed following Cochrane Reviewers' Handbook and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and was carried out by using Stata 14.0 software. Results: Eleven studies concerning intravenous (IV) application of TXA and three studies concerning topical administration of TXA were included. Twelve studies were randomized controlled trials (RCTs), and one was a retrospective cohort study. Regarding IV TXA, our paper indicated that the IV TXA group had less total blood loss (weighted mean difference [WMD] = −319.282, P = 0.000), lower postoperative hemoglobin decline (WMD = −1.14, P = 0.000) and lower transfusion rate (risk difference [RD] = −0.172, P = 0.000). No significant differences were found in thromboembolic events (RD = 0.008, P = 0.507), 90-day mortality (RD = 0.009, P = 0.732) and operative time (WMD = −2.227, P = 0.103). Regarding topical TXA, no significant differences were found in the transfusion rate (RD = −0.098, P = 0.129), postoperative hemoglobin decline (WMD = −1.137, P = 0.231), thromboembolic events (RD = −0.017, P = 0.660) and operative time (WMD = −4.842, P = 0.136).
Introduction
Femoral fracture is a common type of fractures, especially in the elderly. Femoral fracture surgery frequently results in a significant blood loss, which could lead to severe anemia and subsequent need for transfusion, prolonged hospital stay, high hospital cost and a detrimental effect on long-term mortality.
1,2 Blood transfusion could correct anemia, but it could cause complications such as infections, hemolytic reaction, cardiovascular dysfunction and even death. [2] [3] [4] [5] Therefore, it is a significant issue to reduce perioperative blood loss following surgeries for femoral fractures.
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Tranexamic acid (TXA) is a synthetic amino acid analog, which acts as a competitive inhibitor of plasminogen and finally interferes with fibrinolysis. 6 TXA has been reported to be an easily accessible and cost-effective treatment that could reduce the amount of blood loss and subsequent need for blood transfusion, and it has been successfully used in gynecological and obstetric, spinal and thoracic surgeries. [7] [8] [9] In addition, numerous studies have proved that TXA could decrease blood loss and transfusion rates without increasing the rate of thrombotic events in hip and knee arthroplasty. [10] [11] [12] [13] However, there is limited data on the efficacy and safety of TXA usage in femoral fracture surgery; whether TXA should be used in femoral fracture surgery remains controversial. So, we performed this meta-analysis to investigate the efficacy and safety of TXA usage following surgeries for femoral fractures.
Materials and methods
Literature search
Electronic databases were searched before January 20, 2018 by two independent investigators, including Cochrane Library, Embase, Medline and Web of Science. The references of the included literatures were also checked for potentially relevant studies. Only English studies were included. The key words including "tranexamic acid", "fracture", "hemiarthroplasty", "total hip arthroplasty", "total hip replacement", "nail", "screw" and "open reduction internal fixation" were used. They were combined with Boolean operators. The searched results are shown in Figure 1 .
Inclusion and exclusion criteria
Trials were eligible for inclusion if they met the following criteria: 1) studies involved the comparison of the efficacy and safety of TXA usage in femoral fracture surgery and 2) studies included at least one of the outcome measures. Studies were excluded if 1) case reports and publications only included an abstract; 2) they included other types of fractures; 3) they were not published in English and 4) there was duplicate publication.
Data extraction
The following data were independently extracted from each of the included studies by two investigators: first author Records identified through database searching (n = 1,558)
Additional records identified through other sources (n = 1)
Studies included in qualitative synthesis (n = 13)
Full-text articles assessed for eligibility (n = 13)
Records screened (n = 15) 
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Tranexamic acid usage in patients undergoing femoral fracture surgery names, published year, sample size, mean age, anesthesia methods, fracture type, surgical management, intervention, control, thromboprophylaxis, transfusion criteria and follow-up. Disagreement was resolved by consulting the reviewer. The end points included total blood loss, postoperative hemoglobin decline, transfusion rate, thromboembolic events, 90-day mortality and operative time.
Quality assessment
Two investigators independently assessed the quality of the randomized controlled trials (RCTs) according to the methods of the 12-item scale. 14 Each item was scored "Yes", "Unclear" or "No". A trial with a score of more than 7 "Yes" was considered as of high quality, more than 4 but no more than 7 was considered as of moderate quality and no more than 4 was considered as of low quality. The Methodological Index for Non-Randomized Studies (MINORS) criteria was used to assess non-RCTs and was scored from 0 to 24.
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Agreement on the outcome was assessed by the means of a kappa test. Any different opinions were resolved by a third reviewer.
Data analysis and statistical methods
The meta-analysis was conducted using Stata 14.0 software. For continuous outcomes, a weighted mean difference (WMD) and 95% CI were used. For dichotomous data, the risk difference (RD) with 95% CI was calculated as the summary statistics. Statistical heterogeneity was assessed using the value of P and I 2 . If P was .0.1 and I 2 was ,50%, the fixed-effects model was used; otherwise, the random-effects model was used to do analysis. Random-effects models were used to reduce heterogeneity. The assessment of publication bias and meta-regression could not be conducted because the most frequent outcome (transfusion rate) just included nine studies, and tests for them are generally performed only when at least 10 studies are involved. Owing to the limited information, subgroup analyses were just conducted on mean age (,65 years, $65 years). In addition, sensitivity analyses were conducted to insure the accuracy of the outcomes.
ethical approval
All analyses were based on previous published studies; thus, no ethical approval and patient consent were required.
Results
Search result
A total of 1,559 potentially relevant references were founded. After the process of finding duplicates, 670 studies were excluded. By scanning the titles and abstracts, 874 studies were excluded from the analysis. After full texts carefully read for eligibility, two studies were excluded, because they were just an abstract. 16, 17 Finally, 12 RCTs 18-21,23-30 and 1 retrospective cohort study 22 were included. The characteristics of all included studies are shown in Tables 1 and 2 .
Study quality
The quality of RCTs is shown in Table 3 . The value of weighted kappa for the agreement on these studies between reviewers was excellent (κ = 0.72). Ten studies [18] [19] [20] [21] 23, 25, 26, [28] [29] [30] were of high quality, and two studies were of moderate quality. 24, 27 The randomization methods were explicitly introduced in nine studies. [18] [19] [20] 23, 25, 26, [28] [29] [30] Randomization allocation was concealed adequately in six studies. 19, 20, 23, 25, 26, 30 Nine RCTs provided the information of double blinding. 18-21, 23,25,26,28,30 None of them reported a binding of outcome assessment. However, all of the included studies were reported with complete outcome data. The quality of the cohort study is shown in Figure 2 .
Total blood loss (mL)
Intravenous (Iv) administration of TXA Four studies 18, 24, 26, 29 compared total blood loss. The data of them were pooled to do analysis. There was a significant heterogeneity between the studies (P , 0.1, I 2 = 81.9%). Therefore, the random-effects model was used. The pooled results manifested that the IV TXA group had a significant decrease in total blood loss (WMD = −319.282, 95% CI: −475.229 to −163.336, P = 0.000; Figure 3 ).
Postoperative hemoglobin decline (g/dL)
Iv administration of TXA Seven articles 18, [20] [21] [22] [23] [24] 28 reported the outcome of postoperative hemoglobin decline. A significant heterogeneity was detected between the studies (P , 0.1, I 2 = 75.4%). Therefore, the random-effects model was used to do analysis. The pooled results demonstrated that the IV TXA group had a lower postoperative hemoglobin decline (WMD = −1.144, 95% CI: −1.727 to −0.561, P = 0.000; Figure 4 ).
Topical administration of TXA
Two articles 21, 27 reported the outcomes of postoperative hemoglobin decline. A significant heterogeneity was detected between the studies (P , 0.1, I 2 = 92.0%); Therefore, the random-effects model was used to do the analysis. It showed no significant difference in postoperative hemoglobin decline between the topical TXA group and the control group (WMD = −1.137, 95% CI: −2.999 to 0.725, P = 0.231; Figure 4 ). 
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Tranexamic acid usage in patients undergoing femoral fracture surgery Ten studies [18] [19] [20] [21] [22] [23] 26, [28] [29] [30] involved the comparison of transfusion rate. No significant heterogeneity was detected between the studies (P . 0.1, I 2 = 3.8%). Therefore, the fixed-effects model was used to do the analysis. The results showed that the IV TXA group had a lower transfusion rate (RD = −0.172, 95% CI: −0.224 to −0.121, P = 0.000; Figure 5 ).
Topical administration of TXA
Three studies 21, 25, 27 involved the comparison of transfusion rate. There was a significant heterogeneity between the studies (P . 0.1, I 2 = 54.5%). Therefore, the random-effects model was used to do the analysis. It showed no significant difference in the transfusion rate between the two groups (RD = −0.098, 95% CI: −0.225 to 0.029, P = 0.129; Figure 5 ).
Thromboembolic events Iv administration of TXA
Nine studies [19] [20] [21] [22] [23] [24] 26, 29, 30 reported thromboembolic events. No significant heterogeneity was detected (P . 0.1, I 2 = 9.0%), so the fixed-effects model was performed. It showed no significant difference in the rate of thromboembolic events between the two groups (RD = 0.008, 95% CI: −0.017 to 0.034, P = 0.507; Figure 6 ).
Topical administration of TXA
Two studies 21, 25 reported thromboembolic events. No significant heterogeneity was detected (P . 0.1, I 2 = 0%), so the fixed-effects model was performed. There was no significant difference in the rate of thromboembolic events between the two groups (RD = −0.017, 95% CI: −0.091 to 0.058, P = 0.66; Figure 6 ).
90-day mortality
Iv administration of TXA Five studies 18, 22, 26, 29, 30 reported 90-day mortality. No significant heterogeneity was detected (P . 0.1, I 2 = 17%), so the fixedeffects model was performed. It showed no significant 
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Tranexamic acid usage in patients undergoing femoral fracture surgery difference in 90-day mortality between the groups (RD = 0.009, 95% CI: −0.040 to 0.058, P = 0.732; Figure 7 ).
Topical administration of TXA
Only one study 25 reported outcome of mortality. The rate was 13% (13 patients) in the TXA group and 14% (14 patients) in the control group (P . 0.05) during the first 12 months after surgery.
Operative time (min)
Iv administration of TXA The operative time was reported in seven studies. [19] [20] [21] 23, [28] [29] [30] There was no significant heterogeneity between the two groups (P . 0.1, I 2 = 0.0%); therefore, the fixed-effects model was used. The result manifested that no significant difference was detected. (WMD = −2.227, 95% CI: −4.904 to 0.450, P = 0.103; Figure 8 ).
Study ID
Sadeghi and Mehr-Aein (2007) 18 Vijay et al (2013) 20 Emara et al (2014) 21 Mohib et al (2015) 23 Haghighi et al (2017) 28 Baruah et al (2016) 24 Lee et al (2015) 18 Tengberg et al (2016) 26 Mohib et al (2015) 23 Emara et al (2014) 21 Vijay et al (2013) 20 Zufferey et al (2010) 19 Watts et al (2017) 30 Haghighi et al (2017) 28 Lei et al (2017) 29 Lee et al (2015) 22 37 25 Emara et al (2014) 21 Virani et al (2016) 27 39.45 
Topical administration of TXA
The operative time was reported in two studies. 21, 25 There was a significant heterogeneity between the studies (P , 0.1, I 2 = 74.0%). Therefore, the random-effects model was used. The result manifested that no significant difference was detected (WMD = −4.842, 95% CI: −11.214 to 1.530, P = 0.136; Figure 8 ).
Sensitivity analysis
As fewer studies were concerning topical TXA, so we just made sensitivity analysis in outcomes of studies that involved IV TXA usage. All the outcomes kept stable after the exclusion of each study once a time, and it showed some result when using a random effect.
Subgroup analysis
Owing to the lack of related studies, subgroup analysis was just conducted on postoperative hemoglobin decline, transfusion rates and thromboembolic events. 
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Tranexamic acid usage in patients undergoing femoral fracture surgery mean age .65 years group (WMD = −0.565, 95% CI: −0.844 to −0.285, P = 0.000). Concerning transfusion rates, subgroup analysis showed no significant difference regarding mean age ,65 years (RD = −0.239, 95% CI: −0.363 to −0.116, P = 0.000) and mean age .65 years (RD = −0.155, 95% CI: −0.211 to −0.099, P = 0.000). Regarding thromboembolic events, subgroup analysis showed no significant difference regarding mean age ,65 years (RD = 0.053, 95% CI: −0.002 to 0.108, P = 0.061) and mean age .65 years (RD = −0.003, 95% CI: −0.031 to 0.025, P = 0.832).
Discussion
The most important findings of our meta-analysis were that TXA reduced transfusion rate without increasing thromboembolic events in femoral fracture surgery. Although no significant differences were found in the transfusion 
RD (95% CI)
Sadeghi and Mehr-Aein (2007) 18 Tengberg et al (2016) 26 Watts et al (2017) 30 Lei et al (2017) 29 Lee et al (2015) 22
Overall (I 2 = 17.0%, P = 0.307)
Study ID
Figure 7
Forest plot for 90 days mortality. Abbreviations: RD, risk difference; TXA, tranexamic acid.
rate regarding topical TXA, the topical group had a lower transfusion rate compared with the control group. However, a significant heterogeneity was detected in some outcomes. The limited data concerning TXA usage may be contributed to it. The differences in clinical measures should also be taken into consideration. There were limited studies focusing on TXA usage in femoral fracture surgery. Such reasons include older age, female gender, lower admission hemoglobin, higher American Society of Anesthesiologists grade, frailty and greater co-existing comorbidities. Patients suffering from femoral fractures were more susceptible to thromboembolic events comparing with patients undergoing elective joint replacement. 31 Therefore, there is still clinical uncertainty regarding TXA application in femoral fracture patients. However, the potential benefits of TXA in significantly decreasing blood loss and transfusion rates are overwhelming. In addition, TXA could bring improved functional recovery, shorter length of hospital stay and lower cost. 18 Therefore, the potential benefits of TXA in femoral fracture patients may outweigh the risk of it.
Regarding the hemostatic efficacy of IV TXA, all included studies were in favor of its application in femoral fracture surgery. Although some studies found no significant difference in the transfusion rate and/or blood loss, there was a lower transfusion rate and/or blood loss in the TXA group. It is almost a consensus that TXA could reduce blood loss and transfusion rate. Further research on the safety of its usage especially whether it could induce increased thromboembolic events should be carried out. Zufferey et al 19 found a three-fold increased risk in vascular events at 6 weeks with IV TXA usage in hip fracture surgery (P = 0.10), but the incidence rate of vascular events between the IV group and the control group was not statistically significant. Emara et al 21 used thromboelastogram as a monitor for coagulation (significant decrease in r and k and significant increase in maximum amplitude and α-angle), which favored relative hypercoagulable state in the IV TXA group, and they found a statistically significant increase in the incidence of thromboembolic events in the form of deep vein thrombosis (DVT) in the IV TXA group (P , 0.05). However, most included studies proved its safety. 20, [22] [23] [24] 30 At present, the common methods of IV TXA usages are preoperative dose of 1 g or 10-15 mg/kg (sometimes, second dose was added after 3 or 6 h) or combined use of continuous infusion for .8 h. Lanoiselée et al 32 pointed out that TXA plasma concentrations were maintained for .10 mg/L during surgery and for a minimum of 3 h with a preoperative TXA dose of 1 g in hip arthroplasty. However, keeping TXA concentrations above this threshold up to 16 h could not reduce blood loss more effectively. Zufferey et al 33 also reported that a continuous infusion of 1 g TXA after a preoperative bolus of TXA in hip replacement did not achieve any further reduction in blood loss. Piolanti et al 34 divided 80 patients who underwent primary unilateral minimally invasive TXA into two groups: one group received two IV doses of 10 mg/kg of TXA and the other group received two doses of 20 mg/kg. They found that a dose of 10 or 20 mg/kg provides statistically similar results in blood loss sparing, and they pointed that the use of two 10 mg/kg doses could be considered more 
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Tranexamic acid usage in patients undergoing femoral fracture surgery advisable in order to reduce the potential thromboembolic risks. In the trial of Sun et al, 35 180 patients who underwent primary unilateral total knee arthroplasty were randomized into four groups. In group A, TXA (30 mg/kg) was infused 15 min before tourniquet inflation. In group B, TXA (15 mg/ kg) was infused 15 min before tourniquet inflation and 3 h postoperatively. As for group C, TXA (10 mg/kg) was infused 15 min before tourniquet inflation and 3 and 6 h postoperatively. In all, 250 mL of normal saline without TXA was infused 15 min before tourniquet inflation in group D. They concluded that the preoperative dose and an additional dose of TXA were superior to a single preoperative dose of TXA in reducing blood loss and one additional dose was comparable to two additional doses of TXA in reducing blood loss.
Owing to a lack of systemic absorption, topical usage should be taken into consideration. Although no significant differences were found in our meta-analysis, the topical group had a lower transfusion rate. Drakos et al 25 reported that topical TXA used around the fracture site in elderly patients undergoing surgery of intertrochanteric fractures was safe and cost-effective, and a significant reduction in blood loss and transfused blood units and health care cost could be achieved. In addition, Emara et al 21 
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Zhang et al rates was safer comparing with IV TXA. However, Virani et al 27 considered that TXA does not play a significant role in reducing postoperative blood loss and blood transfusion when used locally in pertrochanteric fracture surgery.
Blocking the lysine-binding sites on plasminogen to inhibit the activation of plasminogen and finally interfering with fibrinolysis is the mechanism of TXA. TXA itself does not increase the synthesis of fibrin, so TXA in theory does not lead to a high coagulation state after surgery and certainly not an increase in thromboembolic events. Benoni and Fredin 36 also suggested that TXA does not affect the risk of DVT because it inhibits fibrinolysis in the wound, not in circulation. The Clinical Randomisation of an Antifibrinolytic in Significant Haemarrhage-2 study included 20,000 patients; most of them suffered from significant hemorrhage. It showed that TXA safely reduced the risk of death in bleeding trauma patients. 37 A large sample size study carried out by Poeran et al 38 involving 872,416 patients showed no increased risk of complications, including thromboembolic events and renal failure, with TXA usage in joint replacement surgery.
The key aspects for future research are as follows. 1) High-quality RCTs regarding different TXA dosages and timing still are needed to acquire a better application. 2) The thrombotic risk is of vital importance to its recommendation, so large and high-quality studies should focus on the safety of TXA application, especially in the elderly.
3) The use of topical TXA is a new challenge in controlling intraoperative blood loss among the major orthopedic surgery. RCTs with a larger sample size and a longer follow-up time are necessary to precisely compare IV and topical administrations of TXA. 4) Early surgery has been reported with a lower risk of death and lower rates of postoperative pneumonia and pressure sores among elderly patients with hip fracture. 39 In femoral fractures frequently accompanied by a high initial blood loss, early TXA may decrease the incidence rate of preoperative anemia and then bring an earlier surgery. 5) Most previous studies have excluded patients with significant cardiorespiratory comorbidities and preoperative anemia, which are prevalent features in the elderly fracture population, so whether TXA is safe in these patients needs further research. 6) Combined IV and local TXA has proved efficacy and safety in joint replacement; this kind of TXA administration may be also useful in femoral fracture surgery.
The limitations of this study are as follows. 1) Significant heterogeneity was found in the outcomes of total blood loss and postoperative hemoglobin decline. The differences in TXA dosage, duration, time of administration and number of administered times, fracture type, surgical measurements and transfusion criteria may be contributed to it. As the included studies showed different TXA dosages and timing still, therefore, it was impossible to make subgroup analysis of them across studies. 2) There were very few studies involving topical TXA, so it is hard to make further analysis of it.
3) The publication bias exists.
Conclusion
Our meta-analysis demonstrated that both IV and topical application of TXA reduced transfusion rate in femoral fracture surgery. However, still further studies are needed to identify the optimal route of administration, TXA dosage and timing still. In addition, high-quality RCTs with a large sample size are required to figure out the safety of TXA application, especially in the elderly, before its wide recommendation.
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